EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Disparities in clinical trial participation among older adult Medicare beneficiaries with hematologic malignancies from 2006 to 2019: A SEER–Medicare analysis

Inna Y Gong, Mark J Soto, Bahar Rafinejad-Farahani iD, Joseph M Unger iD, Rena M Conti, Carmen E Guerra, Amit Oza, Meredith Rosenthal, Danielle Rodin

Cancer · 15.12.2025 · 131 (24)

DOI: 10.1002/cncr.70204 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 10.12.2025. Verfasst von Inna Y Gong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Medicare, Hematologic Neoplasms, Clinical Trials as Topic, Healthcare Disparities. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Leukemia and Lymphoma Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials (CTs) are essential for expanding treatment options across hematologic malignancies (HM) and providing access to novel treatments. However, older adults with HM are often underrepresented in CTs, and a national‐level evaluation of factors influencing their participation is lacking.

Methods

The authors conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER)‐Medicare database, identifying patients ≥66 years old diagnosed with HM between 2006 and 2018 (follow‐up to December 2019). CT participation was defined by Medicare claims for CT services. Cumulative incidence and Fine‐Gray models were used to estimate participation rates and adjusted hazard ratios (aHRs) assessed the association between participation and sociodemographic factors.

Results

The cohort ( n = 53,919) was 50% female, median age 78 years old, and 86% White. Cumulative incidence of CT participation was low at 2.7% at 1 year after diagnosis, increasing to 4.3% at 5 years. After adjustment for the competing risk of death, significantly lower CT participation was observed for older age (vs. 66–69 years: aHR for 70–74 years, 0.79 [95% CI, 0.71–0.88]; aHR for 75–79 years, 0.63 [95% CI, 0.56–0.70]; aHR for 80–84 years, 0.41 [95% CI, 0.36–0.46]; aHR for ≥85 years, 0.21 [95% CI, 0.18–0.24]), female sex (aHR, 0.79 [95% CI, 0.73–0.86]), Black race (aHR, 0.73 [95% CI, 0.59–0.90]), certain comorbidities (aHR for pulmonary disease, 0.76 [95% CI, 0.68–0.85]; aHR for renal disease, 0.67 [95% CI, 0.59–0.76]), dual Medicare–Medicaid eligibility (aHR, 0.66 [95% CI, 0.56–0.77]), and distance to National Cancer Institute centers from the patient’s ZIP code (aHR for ≥250 miles, 0.64 [95% CI, 0.48–0.86]).

Conclusions

These results highlight the need for targeted interventions, such as CT navigator programs and decentralized trials, to increase older adult participation in HM CTs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedicareHematologic NeoplasmsClinical Trials as TopicHealthcare DisparitiesPatient ParticipationHumansAgedFemaleUnited StatesMaleSEER ProgramAged, 80 and overRetrospective Studies

Stichwörter der Autor:innen

clinical trialhealth care disparitieshealth inequitieshematologic neoplasmleukemialymphomamultiple myelomaolder adults

Autor:innen und Institutionen

  • Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Global Cancer Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Markets, Public Policy, and Law, Boston University Questrom School of Business, Boston, Massachusetts, USA.

ORCID-Profile: Bahar Rafinejad-Farahani, Joseph M Unger

Förderung

  • Leukemia and Lymphoma Society

Zitieren

APA

Gong, I. Y., Soto, M. J., Rafinejad-Farahani, B., Unger, J. M., Conti, R. M., Guerra, C. E., Oza, A., Rosenthal, M., & Rodin, D. (2025). Disparities in clinical trial participation among older adult Medicare beneficiaries with hematologic malignancies from 2006 to 2019: A SEER–Medicare analysis. Cancer, 131(24). https://doi.org/10.1002/cncr.70204

Vancouver

Gong IY, Soto MJ, Rafinejad-Farahani B, Unger JM, Conti RM, Guerra CE, et al. Disparities in clinical trial participation among older adult Medicare beneficiaries with hematologic malignancies from 2006 to 2019: A SEER–Medicare analysis. Cancer. 2025;131(24). doi:10.1002/cncr.70204

BibTeX
@article{Gong2025,
  author = {Gong, Inna Y and Soto, Mark J and Rafinejad-Farahani, Bahar and Unger, Joseph M and Conti, Rena M and Guerra, Carmen E and Oza, Amit and Rosenthal, Meredith and Rodin, Danielle},
  title = {Disparities in clinical trial participation among older adult Medicare beneficiaries with hematologic malignancies from 2006 to 2019: A SEER–Medicare analysis},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {24},
  doi = {10.1002/cncr.70204}
}
Kostenlos starten →